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Self-interacting BAX proteins permeabilize outermitochondrial membranes to trigger apoptotic cell
death. Czabotar et al. present two revealing structures of BAX dimers: one dimer has an activator
BH3 helix bound into its canonical cleft, and the other dimer exposes a planar hydrophobic face
potentially critical for membrane interactions.Three structurally similar proteins, BAX,
BID, and BCL-xL, interact in all possible
heterodimer combinations to regulate
mammalian apoptosis at mitochondria.
BAX uniquely has the capacity to form
higher-order oligomers on the outer mito-
chondrial membrane, leading to mem-
brane permeabilization and cell death,
but details of these crucial events are
not known. BAX is activated by BID (after
BID is cleaved to form tBID) and is in-
hibited by BCL-xL and other prosurvival
BCL-2 family members. Both BAX and
tBID engage their prosurvival partner by
directly inserting their BH3-helix (a2) into
a hydrophobic cleft on prosurvival pro-
teins. Thus, BH3 mimetics are being ex-
ploited as therapeutics to kill tumor cells
by inactivating prosurvival proteins. The
BH3 helices of tBID and other BH3-only
proteins are also thought to engage the
analogous binding cleft on BAX during
its activation, but these fleeting interac-
tions have been difficult to capture, and
no three-dimensional (3D) structures
were previously available to support this
model. Also absent are structures to
explain how BAX monomers fit together
as oligomers. The very act of exposing
the hidden binding face of a BH3 helix to
engage the cleft of a partner molecule
requires complex structural rearrange-
ments, yet nothing was known about
these alternative structures or their transi-
tion states. In this issue of Cell, Czabotar
and colleagues provide the first glimpse
of such events, revealed by several new
structures of BAX (Czabotar et al., 2013).
Using peptides corresponding to the
BH3 helix of BID, Czabotar et al. (2013)
induced dimerization of purified BAX
(minus its C-terminal transmembrane
a helix 9, which prevents a9 from occu-pying the same cleft, characteristic of
BAX monomers). In the resulting crystal
structure, BAX is a domain-swap dimer
analogous to a domain-swap dimer struc-
ture of BCL-xL (O’Neill et al., 2006). This
dimer is structurally equivalent to two
monomers joined at the hip (bottom of
the central helical hairpin a5–a6), except
that the central helical hairpin has been
splayed open into a pair of extended
helices, such that the N-terminal five
helices (‘‘core’’ domain) of one BAX mole-
cule engages the C-terminal helixes a6–
a8 (‘‘latch’’ domain) of the second BAX
molecule in the usual way (Figure 1A).
Although Czabotar et al. (2013) agree
with the general consensus that the dimer
swapmaynot be biological, two important
revelations emerge from this structure.
In the domain-swap dimer of BAX, the
BH3 peptide of BID occupies the canon-
ical binding cleft of BAX, which is consis-
tent with previous biochemical studies
(Dewson et al., 2012). This contrasts
with the only other reported structure of
BAX bound to a BH3 peptide. In that
structure, the BH3 helix of BIM, another
direct activator of BAX, binds to a
‘‘trigger’’ pocket located on the opposite
face of BAX and not in the canonical cleft
(Gavathiotis et al., 2008). Importantly,
Czabotar et al. (2013) show that side
chains of BH3 peptides satisfyingly distin-
guish the binding specificities of two
subclasses of BH3-only proteins, the
direct (e.g., BID and BIM) versus indirect
activators (e.g., NOXA and BAD, which
bind to prosurvival proteins rather than
BAX). Key amino acid substitutions
convert NOXA and BAD peptides into
direct activators of BAX. Furthermore,
some of the critical BH3 side chains are
not likely used for binding the triggerCell 152pocket. However, a key residue in BIM
(L152) appears to be important for binding
both the canonical cleft and to the trigger
pocket of BAX (Gavathiotis et al., 2008).
Thus, it can be challenging to distinguish
different binding sites, at least for BIM. It
is also puzzling that the BH3 helix of BIM
can induce BAX domain-swap dimers,
yet BIM is noticeably absent from the re-
sulting crystal structure.
To address a potential role for the BAX
BH3 helix in BAX oligomerization, Czabo-
tar et al. (2013) also solved a crystal struc-
ture of BAX-induced BAX dimers. In this
domain-swap dimer, the canonical cleft
is occupied by a BH3 peptide of BAX
itself, implying that this is a key interface
in the deadly BAX oligomer. Additional
biochemical evidence indicates that a
cleft-occluded mutant of BAX does not
bind the wild-type BAX BH3 peptide until
a compensatory mutation is placed in
the BAX peptide. This cleft-occluded
mutant could also be useful to provide
the needed confirmation of specific bind-
ing by BID and BIM in the canonical cleft.
Nevertheless, these studies provide
important information that helps to define
BH3 sequence motifs, a problem that
continues to plague the field (Aouacheria
et al., 2012).
The second revelation arising from the
domain-swap BAX dimer is a novel model
of BAX activation. A BH3-induced cavity
appears in the domain-swap dimer at
the point where BAX will open to separate
the C-terminal ‘‘latch’’ (helices a6–a8)
from the N-terminal ‘‘core’’ domain
(a2–a5). A similar cavity is not found in
the BCL-xL-BIM structure, potentially ex-
plaining why BAX is more readily destabi-
lized by invading BH3 helices. Thus, it is
proposed that an invading BH3 helix, January 31, 2013 ª2013 Elsevier Inc. 383
Figure 1. Novel BAX Dimer Structure
Reveals Potential Membrane Interaction
Face
(A) Schematic of two dimer structures presented in
Czabotar et al. (2013).
(B) Novel ‘‘core’’ dimer structure of BAX formed by
swapping the BH3 (helix 2) of onemolecule into the
position of the BH3 (helix 2) of the othermolecule to
create a relatively flat hydrophobic surface con-
sisting of helices 4 and 5. Diagram represents
a top-down view of the dimer with a membrane in
the plane of the page. The locations of helices a1
and a6–a8 are inferred and are in gray to delineate.
(C) Rotated view of the central a4–a5 helices, in
which 12 bulky hydrophobic side chains orient
toward the membrane. Helices may either directly
embed into the membrane to alter membrane
structure or possibly reorient to form the a5–a6
helical hairpin. Lipids in bold indicate displacement
of molecules due to helix integration into the mem-
brane, leading to changes in membrane curvature.liberates not just the buried BAXBH3 helix
but also the entire ‘‘core’’ domain. To
provide further evidence that there is an
alternative outcome after unlatching BAX
other than the domain-swap dimer, Cza-
botar et al. (2013) solved a very intriguing
crystal structure of the N-terminal ‘‘core’’
domain alone (a2–a5), referred to as the
‘‘BH3-in-groove’’ structure (Figure 1A).
This structure is a surprise. The ‘‘core’’
domain forms a novel dimer in which the
BH3 (a2) of one molecule invades the
second molecule in the same orientation
as the monomer (Figure 1B). The startling384 Cell 152, January 31, 2013 ª2013 Elseviefeature of this ‘‘core’’ dimer is the expo-
sure of a large roughly planar hydrophobic
surface as a potential membrane-embed-
ding surface (Figure 1C). To ask whether
this novel structure exists in cells, they
tested the predicted proximity of the two
BH3 (a2) helices unique to this dimer. As
predicted, a Cys residue placed at Glu69
resulted in a Cys69-Cys69 crosslinked
dimer. Remarkably, 12 conserved bulky
aromatic residues protrude from the
hydrophobic surface formed by helices
a4 and a5 (Figure 1C). The positions of
helices a1 and a6–a8 were not deter-
mined in this structure, but it appears
that both the ‘‘trigger’’ binding pocket
and the canonical cleft are disrupted,
which is consistent with release of acti-
vator BH3 proteins prior to BAX oligomer-
ization (Figure 1B).
To test whether opening of the helical
hairpin (a5–a6) is important to unlatch
the ‘‘core’’ domain as proposed, Czabotar
et al. (2013) tethered a5 to a6 by cross-
linking, which allowed binding to BH3
peptides but abolished tBID-induced
cytochrome c release and BAX dimeriza-
tion. This model of BAX activation differs
from that proposed for BIM-activated
BAX, where the BIM BH3 displaces a1–
a2 upon binding the ‘‘trigger’’ pocket,
which in turn is suggested to release the
tail anchor a9 from the opposite face and
subsequently liberate the buried BH3
helix, making it available to interact with
the next partner (Gavathiotis et al., 2010).
Whether a1 is part of the ‘‘core’’ or the
‘‘latch’’ is not definitively resolved and
would depend on the flexibility of the
loop separating a1 and a2. A recently re-
ported NMR structure of BAX complexed
with a peptide of vMIA, a viral apoptosis
inhibitor, revealed a third distinct binding
site on BAX nestled between the a3–4
and a5–6 hairpins (Ma et al., 2012). vMIA
is a potent inhibitor of BAX-induced cell
death, yet vMIA recruits BAX tomitochon-
dria and does not prevent BAX oligomeri-
zation (Arnoult et al., 2004; Poncet et al.,
2004). One could guess that, by binding
near the a5–a6 hairpin hinge, vMIA could
prevent unlatching or alter membrane
interactions.
This BAX ‘‘core’’ dimer structure poten-
tially challenges previous models regard-
ing the central helical hairpin (a5–a6),
a defining characteristic of BCL-2 family
members in solution structures. Afterr Inc.insertion of the tail anchor (a9) of BAX
and of other BCL-2 proteins into mem-
branes, the helical hairpin apparently
inserts intomembranes toaltermembrane
curvature and facilitate pore forma-
tion, based on in vitro liposome studies
(Basan˜ez et al., 2002) (Figure 1C). Perhaps
the tilted helix a5 could project into the
membrane in amanner consistent with re-
forming the a5–a6 hairpin or alternative
structure to modulate membrane shape.
This model is consistent with the ‘‘core’’
dimer representing a transition state in
route to the BAX oligomer, as suggested.
The final endpoint for BAX remains to be
solved. Collectively, these new structures
open new opportunities for the develop-
ment of small molecules that either acti-
vate or suppress BAX activation to modu-
late cell death for therapeutic benefit.
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